A citation-based method for searching scientific literature

Peter Savas, Roberto Salgado, Carsten Denkert, Christos Sotiriou, Phillip K Darcy, Mark J Smyth, Sherene Loi. Nat Rev Clin Oncol 2016
Times Cited: 435







List of co-cited articles
697 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
28

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, S Wienert, G Van den Eynden, F L Baehner, F Penault-Llorca,[...]. Ann Oncol 2015
28

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Barbara I Heppner, Karsten E Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto,[...]. Lancet Oncol 2018
764
27

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
20

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Sherene Loi, Nicolas Sirtaine, Fanny Piette, Roberto Salgado, Giuseppe Viale, Françoise Van Eenoo, Ghizlane Rouas, Prudence Francis, John P A Crown, Erika Hitre,[...]. J Clin Oncol 2013
18

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, P-L Kellokumpu-Lehtinen, P Bono, V Kataja, C Desmedt,[...]. Ann Oncol 2014
788
18

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.
Carsten Denkert, Sibylle Loibl, Aurelia Noske, Marc Roller, Berit Maria Müller, Martina Komor, Jan Budczies, Silvia Darb-Esfahani, Ralf Kronenwett, Claus Hanusch,[...]. J Clin Oncol 2010
17

Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid, Javier Cortes, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck,[...]. N Engl J Med 2020
647
17

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
Sherene Loi, Damien Drubay, Sylvia Adams, Giancarlo Pruneri, Prudence A Francis, Magali Lacroix-Triki, Heikki Joensuu, Maria Vittoria Dieci, Sunil Badve, Sandra Demaria,[...]. J Clin Oncol 2019
299
16

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Javier Cortes, David W Cescon, Hope S Rugo, Zbigniew Nowecki, Seock-Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H Barrios, Esther Holgado,[...]. Lancet 2020
381
15

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Rita Nanda, Laura Q M Chow, E Claire Dees, Raanan Berger, Shilpa Gupta, Ravit Geva, Lajos Pusztai, Kumudu Pathiraja, Gursel Aktan, Jonathan D Cheng,[...]. J Clin Oncol 2016
870
14


Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
Sylvia Adams, Robert J Gray, Sandra Demaria, Lori Goldstein, Edith A Perez, Lawrence N Shulman, Silvana Martino, Molin Wang, Vicky E Jones, Thomas J Saphner,[...]. J Clin Oncol 2014
764
14

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Peter Schmid, Hope S Rugo, Sylvia Adams, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Volkmar Henschel, Luciana Molinero, Stephen Y Chui,[...]. Lancet Oncol 2020
438
14

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Luc Y Dirix, Istvan Takacs, Guy Jerusalem, Petros Nikolinakos, Hendrik-Tobias Arkenau, Andres Forero-Torres, Ralph Boccia, Marc E Lippman, Robert Somer, Martin Smakal,[...]. Breast Cancer Res Treat 2018
357
13

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
Carsten Denkert, Gunter von Minckwitz, Jan C Brase, Bruno V Sinn, Stephan Gade, Ralf Kronenwett, Berit M Pfitzner, Christoph Salat, Sherene Loi, Wolfgang D Schmitt,[...]. J Clin Oncol 2015
639
13

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Maria Vittoria Dieci, Nina Radosevic-Robin, Susan Fineberg, Gert van den Eynden, Nils Ternes, Frederique Penault-Llorca, Giancarlo Pruneri, Timothy M D'Alfonso, Sandra Demaria, Carlos Castaneda,[...]. Semin Cancer Biol 2018
191
12

The immune contexture in human tumours: impact on clinical outcome.
Wolf Herman Fridman, Franck Pagès, Catherine Sautès-Fridman, Jérôme Galon. Nat Rev Cancer 2012
12

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
S Adams, S Loi, D Toppmeyer, D W Cescon, M De Laurentiis, R Nanda, E P Winer, H Mukai, K Tamura, A Armstrong,[...]. Ann Oncol 2019
273
12

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.
H R Ali, E Provenzano, S-J Dawson, F M Blows, B Liu, M Shah, H M Earl, C J Poole, L Hiller, J A Dunn,[...]. Ann Oncol 2014
428
11

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
S Adams, P Schmid, H S Rugo, E P Winer, D Loirat, A Awada, D W Cescon, H Iwata, M Campone, R Nanda,[...]. Ann Oncol 2019
331
11


Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Leisha A Emens, Cristina Cruz, Joseph Paul Eder, Fadi Braiteh, Cathie Chung, Sara M Tolaney, Irene Kuter, Rita Nanda, Philippe A Cassier, Jean-Pierre Delord,[...]. JAMA Oncol 2019
348
10

Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.
Peter Savas, Balaji Virassamy, Chengzhong Ye, Agus Salim, Christopher P Mintoff, Franco Caramia, Roberto Salgado, David J Byrne, Zhi L Teo, Sathana Dushyanthen,[...]. Nat Med 2018
411
10

Breast Cancer Immunotherapy: Facts and Hopes.
Leisha A Emens. Clin Cancer Res 2018
288
10

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
10

Clinical significance of tumor-infiltrating lymphocytes in breast cancer.
Sasha E Stanton, Mary L Disis. J Immunother Cancer 2016
292
10

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Elizabeth A Mittendorf, Hong Zhang, Carlos H Barrios, Shigehira Saji, Kyung Hae Jung, Roberto Hegg, Andreas Koehler, Joohyuk Sohn, Hiroji Iwata, Melinda L Telli,[...]. Lancet 2020
257
10

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Roberto Salgado, Carsten Denkert, Christine Campbell, Peter Savas, Paolo Nuciforo, Claudia Aura, Evandro de Azambuja, Holger Eidtmann, Catherine E Ellis, Jose Baselga,[...]. JAMA Oncol 2015
349
9

Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.
Sahar M A Mahmoud, Emma Claire Paish, Desmond G Powe, R Douglas Macmillan, Matthew J Grainge, Andrew H S Lee, Ian O Ellis, Andrew R Green. J Clin Oncol 2011
917
9



Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
9

Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
J H Park, S F Jonas, G Bataillon, C Criscitiello, R Salgado, S Loi, G Viale, H J Lee, M V Dieci, S-B Kim,[...]. Ann Oncol 2019
88
10

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
P Schmid, R Salgado, Y H Park, E Muñoz-Couselo, S B Kim, J Sohn, S-A Im, T Foukakis, S Kuemmel, R Dent,[...]. Ann Oncol 2020
129
9


Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
8

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
Jérôme Galon, Anne Costes, Fatima Sanchez-Cabo, Amos Kirilovsky, Bernhard Mlecnik, Christine Lagorce-Pagès, Marie Tosolini, Matthieu Camus, Anne Berger, Philippe Wind,[...]. Science 2006
8

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, Yu Shyr, Jennifer A Pietenpol. J Clin Invest 2011
8

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
8

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Rita Nanda, Minetta C Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai, Anne Wallace, A Jo Chien, Andres Forero-Torres, Erin Ellis, Heather Han,[...]. JAMA Oncol 2020
211
8

PD-L1 expression in triple-negative breast cancer.
Elizabeth A Mittendorf, Anne V Philips, Funda Meric-Bernstam, Na Qiao, Yun Wu, Susan Harrington, Xiaoping Su, Ying Wang, Ana M Gonzalez-Angulo, Argun Akcakanat,[...]. Cancer Immunol Res 2014
696
8



CD4⁺ follicular helper T cell infiltration predicts breast cancer survival.
Chunyan Gu-Trantien, Sherene Loi, Soizic Garaud, Carole Equeter, Myriam Libin, Alexandre de Wind, Marie Ravoet, Hélène Le Buanec, Catherine Sibille, Germain Manfouo-Foutsop,[...]. J Clin Invest 2013
547
7

Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.
Stephen J Luen, Peter Savas, Stephen B Fox, Roberto Salgado, Sherene Loi. Pathology 2017
72
9

Oncology meets immunology: the cancer-immunity cycle.
Daniel S Chen, Ira Mellman. Immunity 2013
7

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
7

Breast Cancer Treatment: A Review.
Adrienne G Waks, Eric P Winer. JAMA 2019
7

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
M V Dieci, M C Mathieu, V Guarneri, P Conte, S Delaloge, F Andre, A Goubar. Ann Oncol 2015
185
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.